Evaluación de la calidad del agua en un río subtropical y tributarios utilizando índices fisicoquímicos y macroinvertebrados acuáticos

Background. The evaluation of the integrity of a river involves the analysis of different aspects of its environment and the ecosystem itself. Goal. In the present study, the abiotic and biotic quality of the Cupatitzio river was characterized using multiple indicators. Methods. An analysis of the coverage of the different land uses in the basin was carried out, 16 physicochemical variables of the water were measured, and aquatic invertebrates were identified and quantified in 20 monitoring sites. Water quality index (NSF-WQI) and biological indices (Shannon-Wiener, Pielou, and Indicator Species Analysis) were calculated, and multivariate statistical methods were applied. Results. Most of the sites present an important coverage of human settlements and agriculture, and the lowest value for natural vegetation. Consequently, the beginning of the river presented a modification in its channel which reduced the value of biological indicators. Overall water quality is medium for the river, related to the presence of organic matter with high values of Biochemical Oxygen Demand (maximum 22.82 mg/L) and nutrients (maximum NO3 of 12.39 mg/L and NH4 of 7.31 mg/L). The dominant families were Chironomidae, Lumbriculidae, Gammaridae, and Baetidae. A significant spatial and temporal difference in family abundance was detected (A=0.061, P=0.0007, and A=0.247, P=0.000008, respectively). Six of the 77 families were identified as significant indicators. Conclusions. Only at dry season there was more concordance between environmental quality and aquatic organisms’ indicators. A protocol of the analyses is presented for implementation in other aquatic ecosystems and it is recommended the necessity to calibrate and validate biological indicator indices (e. g., BMWP) to improve interpretation.Antecedentes. La evaluación de la integridad de un río involucra el análisis de diferentes aspectos de su entorno y del propio ecosistema. Objetivos. En el presente estudio se caracterizó la calidad abiótica y biótica del río Cupatitzio utilizando múltiples indicadores. Métodos. Se realizó un análisis de la cobertura de los diferentes usos del suelo en la cuenca, se registraron 16 variables fisicoquímicos del agua, se identificaron y cuantificaron los invertebrados acuáticos en 20 sitios. Se calcularon el índice de calidad del agua (NSFWQI) y los índices biológicos (Shannon-Wiener, Pielou e Indicator Species Analysis) y se aplicaron métodos estadísticos multivariados. Resultados. La mayoría de los sitios presentan una importante cobertura de asentamientos humanos y agricultura con el menor valor para la vegetación natural. En consecuencia, el inicio del río presentó una modificación en su cauce lo que redujo el valor de los indicadores biológicos. La calidad del agua es mayormente media, relacionada a la presencia de materia orgánica con altos valores de Demanda Bioquímica de Oxígeno (máximo de 22.82 mg/L) y nutrientes (máximos de NO3 de 12.39 mg/L y NH4 de 7.31 mg/L). Las familias dominantes fueron Chironomidae, Lumbriculidae, Gammaridae y Baetidae. Se detectó una diferencia significativa tanto espacial como temporal en la abundancia de las familias (A=0.061, P=0.0007 y A=0.247, P=0.000008, respectivamente). Se identificaron 6 de las 77 familias como indicadores significativos. Conclusiones. Solo en estiaje se presentó más concordancia entre la calidad ambiental y los macroinvertebrados indicadores. Se presenta un protocolo de análisis para su implementación en otros ecosistemas acuáticos y se ve la necesidad de incorporar otros índices de indicadores biológicos (p. ej., BMWP) calibrados y validados para mejorar la interpretación

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

SummaryBackground Azithromycin has been proposed as a treatment for COVID-19 on the basis of its immunomodulatoryactions. We aimed to evaluate the safety and efficacy of azithromycin in patients admitted to hospital with COVID-19.Methods In this randomised, controlled, open-label, adaptive platform trial (Randomised Evaluation of COVID-19Therapy [RECOVERY]), several possible treatments were compared with usual care in patients admitted to hospitalwith COVID-19 in the UK. The trial is underway at 176 hospitals in the UK. Eligible and consenting patients wererandomly allocated to either usual standard of care alone or usual standard of care plus azithromycin 500 mg once perday by mouth or intravenously for 10 days or until discharge (or allocation to one of the other RECOVERY treatmentgroups). Patients were assigned via web-based simple (unstratified) randomisation with allocation concealment andwere twice as likely to be randomly assigned to usual care than to any of the active treatment groups. Participants andlocal study staff were not masked to the allocated treatment, but all others involved in the trial were masked to theoutcome data during the trial. The primary outcome was 28-day all-cause mortality, assessed in the intention-to-treatpopulation. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936.Findings Between April 7 and Nov 27, 2020, of 16 442 patients enrolled in the RECOVERY trial, 9433 (57%) wereeligible and 7763 were included in the assessment of azithromycin. The mean age of these study participants was65·3 years (SD 15·7) and approximately a third were women (2944 [38%] of 7763). 2582 patients were randomlyallocated to receive azithromycin and 5181 patients were randomly allocated to usual care alone. Overall,561 (22%) patients allocated to azithromycin and 1162 (22%) patients allocated to usual care died within 28 days(rate ratio 0·97, 95% CI 0·87–1·07; p=0·50). No significant difference was seen in duration of hospital stay (median10 days [IQR 5 to >28] vs 11 days [5 to >28]) or the proportion of patients discharged from hospital alive within 28 days(rate ratio 1·04, 95% CI 0·98–1·10; p=0·19). Among those not on invasive mechanical ventilation at baseline, nosignificant difference was seen in the proportion meeting the composite endpoint of invasive mechanical ventilationor death (risk ratio 0·95, 95% CI 0·87–1·03; p=0·24).Interpretation In patients admitted to hospital with COVID-19, azithromycin did not improve survival or otherprespecified clinical outcomes. Azithromycin use in patients admitted to hospital with COVID-19 should be restrictedto patients in whom there is a clear antimicrobial indication

Clinical and genetic characteristics of late-onset Huntington's disease

Background: The frequency of late-onset Huntington's disease (>59 years) is assumed to be low and the clinical course milder. However, previous literature on late-onset disease is scarce and inconclusive. Objective: Our aim is to study clinical characteristics of late-onset compared to common-onset HD patients in a large cohort of HD patients from the Registry database. Methods: Participants with late- and common-onset (30–50 years)were compared for first clinical symptoms, disease progression, CAG repeat size and family history. Participants with a missing CAG repeat size, a repeat size of ≤35 or a UHDRS motor score of ≤5 were excluded. Results: Of 6007 eligible participants, 687 had late-onset (11.4%) and 3216 (53.5%) common-onset HD. Late-onset (n = 577) had significantly more gait and balance problems as first symptom compared to common-onset (n = 2408) (P <.001). Overall motor and cognitive performance (P <.001) were worse, however only disease motor progression was slower (coefficient, −0.58; SE 0.16; P <.001) compared to the common-onset group. Repeat size was significantly lower in the late-onset (n = 40.8; SD 1.6) compared to common-onset (n = 44.4; SD 2.8) (P <.001). Fewer late-onset patients (n = 451) had a positive family history compared to common-onset (n = 2940) (P <.001). Conclusions: Late-onset patients present more frequently with gait and balance problems as first symptom, and disease progression is not milder compared to common-onset HD patients apart from motor progression. The family history is likely to be negative, which might make diagnosing HD more difficult in this population. However, the balance and gait problems might be helpful in diagnosing HD in elderly patients

Reduced Cancer Incidence in Huntington's Disease: Analysis in the Registry Study

Background: People with Huntington's disease (HD) have been observed to have lower rates of cancers. Objective: To investigate the relationship between age of onset of HD, CAG repeat length, and cancer diagnosis. Methods: Data were obtained from the European Huntington's disease network REGISTRY study for 6540 subjects. Population cancer incidence was ascertained from the GLOBOCAN database to obtain standardised incidence ratios of cancers in the REGISTRY subjects. Results: 173/6528 HD REGISTRY subjects had had a cancer diagnosis. The age-standardised incidence rate of all cancers in the REGISTRY HD population was 0.26 (CI 0.22-0.30). Individual cancers showed a lower age-standardised incidence rate compared with the control population with prostate and colorectal cancers showing the lowest rates. There was no effect of CAG length on the likelihood of cancer, but a cancer diagnosis within the last year was associated with a greatly increased rate of HD onset (Hazard Ratio 18.94, p < 0.001). Conclusions: Cancer is less common than expected in the HD population, confirming previous reports. However, this does not appear to be related to CAG length in HTT. A recent diagnosis of cancer increases the risk of HD onset at any age, likely due to increased investigation following a cancer diagnosis

Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)

In 2008, we published the first set of guidelines for standardizing research in autophagy. Since then, this topic has received increasing attention, and many scientists have entered the field. Our knowledge base and relevant new technologies have also been expanding. Thus, it is important to formulate on a regular basis updated guidelines for monitoring autophagy in different organisms. Despite numerous reviews, there continues to be confusion regarding acceptable methods to evaluate autophagy, especially in multicellular eukaryotes. Here, we present a set of guidelines for investigators to select and interpret methods to examine autophagy and related processes, and for reviewers to provide realistic and reasonable critiques of reports that are focused on these processes. These guidelines are not meant to be a dogmatic set of rules, because the appropriateness of any assay largely depends on the question being asked and the system being used. Moreover, no individual assay is perfect for every situation, calling for the use of multiple techniques to properly monitor autophagy in each experimental setting. Finally, several core components of the autophagy machinery have been implicated in distinct autophagic processes (canonical and noncanonical autophagy), implying that genetic approaches to block autophagy should rely on targeting two or more autophagy-related genes that ideally participate in distinct steps of the pathway. Along similar lines, because multiple proteins involved in autophagy also regulate other cellular pathways including apoptosis, not all of them can be used as a specific marker for bona fide autophagic responses. Here, we critically discuss current methods of assessing autophagy and the information they can, or cannot, provide. Our ultimate goal is to encourage intellectual and technical innovation in the field